Vaxcyte (PCVX) Earnings Date & Reports

Key Takeaways

• Vaxcyte is expected to report Q2 2026 results on or around August 5, 2026, with consensus estimates pointing to a net loss of approximately $2.07 per share, compared to a loss of $1.22 in the same quarter last year.
• The company has missed earnings per share (EPS) estimates for five consecutive quarters, including a 28.5% miss in Q1 2026, as research and development (R&D) costs accelerate faster than anticipated.
• Cash remains a relative strength. As of March 31, 2026, Vaxcyte held $2.74 billion in cash, equivalents, and investments, supplemented by a $600 million equity raise earlier in the year, providing a runway into at least late 2028.
• The VAX-31 pneumococcal conjugate vaccine (PCV) program is the centerpiece of investor focus, with three pivotal Phase 3 OPUS trials underway and the first top-line data readout expected in the fourth quarter of 2026.
• Analysts remain overwhelmingly bullish, with a consensus "Strong Buy" rating and an average 12-month price target of approximately $109, implying roughly 100% upside from recent trading levels around $55.

Earnings Context and Why It Matters

Vaxcyte is a clinical-stage biotechnology company with no approved products and no material revenue, meaning its quarterly reports are fundamentally about two things: cash burn and clinical progress. The Q2 2026 update lands at a pivotal moment. The company is simultaneously running three large Phase 3 adult trials for VAX-31, a Phase 2 infant study, and has just dosed the first participant in a Phase 1 trial for VAX-A1, its Group A Streptococcus vaccine candidate. With R&D expenses having more than doubled year-over-year in Q1 2026 to $312.8 million, investors are keen to see whether spending is tracking in line with expectations and whether management reaffirms its timeline for key data readouts. In a market where patience for pre-revenue biotech can wear thin, the tone of this report matters as much as the numbers.

Earnings Expectations

Wall Street analysts expect Vaxcyte to report a net loss of roughly $2.07 per share for the second quarter of 2026, according to consensus data compiled by TipRanks and Benzinga. That represents a year-over-year widening of approximately 70% from the $1.22 per-share loss recorded in Q2 2025. Revenue expectations are modest — consensus estimates hover around $12.5 million, reflecting limited collaboration or grant income rather than product sales. R&D expenses are the figure to watch most closely. In Q1 2026, R&D spending surged to $312.8 million, up from $148.1 million a year earlier, driven by manufacturing scale-up, clinical trial enrollment across the OPUS program, and headcount growth. General and administrative (G&A) expenses remained relatively stable at $33.1 million. The company's history of negative earnings surprises — it has missed consensus EPS estimates for five consecutive quarters — adds an element of caution heading into this report.

AI Screener

For investors tracking how clinical-stage biotech names like Vaxcyte behave around earnings and major catalysts, Tickeron's AI Screener offers a data-driven way to filter the market. The AI Screener is an AI-powered stock and ETF discovery tool that allows traders and investors to scan thousands of securities using customizable filters, including industry classification, market capitalization, technical indicators, price patterns, and performance metrics. It helps identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. Whether you are monitoring biotech earnings trends or searching for stocks exhibiting specific technical or fundamental signals, the AI Screener can help streamline your research process.

Market Reaction and Investor Sentiment

Sentiment heading into Vaxcyte's Q2 2026 earnings report appears cautiously constructive but not euphoric. The stock has pulled back roughly 15% from its 52-week high of $65.00, reached in late February, and currently trades near $55. Shares are still up approximately 18% year-to-date, supported by positive clinical developments — including completion of enrollment in the VAX-31 infant Phase 2 study and the initiation of the VAX-A1 Phase 1 trial — as well as a favorable competitive landscape in which several rival high-valent PCV programs have been deprioritized or delayed. However, the company's pattern of exceeding loss expectations is a well-known risk. The post-earnings stock reaction will likely hinge on whether R&D expense growth comes in at or below Street forecasts, and whether management offers any incremental color on the OPUS-1 data timeline beyond the existing "Q4 2026" guidance.

Forward Outlook and Key Factors to Monitor

Looking beyond the Q2 print, the single most important near-term catalyst for Vaxcyte is the OPUS-1 Phase 3 top-line data readout, expected in the fourth quarter of 2026. OPUS-1 is a pivotal non-inferiority study comparing VAX-31 to both Pfizer's Prevnar 20 and Merck's Capvaxive (a PCV, or pneumococcal conjugate vaccine). Investors and analysts will be focused on whether VAX-31 meets the statistical bar for the shared serotypes and how it performs on the incremental strains that represent its value proposition.

Two additional Phase 3 readouts — OPUS-2 and OPUS-3 — are expected in the first half of 2027, followed by a potential Biologics License Application (BLA) submission later that year. On the infant side, the VAX-31 Phase 2 study has completed enrollment of 900 infants, with primary three-dose and booster data also anticipated in the first half of 2027.

Cost trends remain a critical variable. Manufacturing investments, including a newly completed large-scale production facility and a fill-finish build-out in North Carolina, are part of a commitment of up to $1 billion in U.S. manufacturing infrastructure. While these expenditures are essential for commercial readiness, they will continue to pressure the income statement. On the competitive front, Vaxcyte's lead appears to have widened as peers including Pfizer, Sanofi, and GSK have deprioritized or delayed their own high-valent adult PCV candidates. This dynamic could provide Vaxcyte with a valuable first-mover advantage in the broader-spectrum PCV market if VAX-31 delivers positive Phase 3 data. The initiation of the VAX-A1 Phase 1 program also adds a secondary pipeline catalyst, with initial safety and tolerability data expected in the second half of 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations